XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Cash flows from operating activities:              
Net loss $ (35,534,533) $ (40,649,317) $ (108,497,311) $ (79,073,719) $ (76,183,850) $ (187,571,030)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         1,410,649 1,869,961  
Amortization of intangible assets         145,417 257,327  
Amortization of operating lease right-of-use assets         739,469 658,501  
Impairment of intangible assets         1,984,444 0  
Non-cash stock-based compensation         6,727,000 16,047,204  
Non-cash interest on senior convertible notes         93,489 93,489  
Amortization of discounts on investments         (2,402,451) (72,833)  
Loss on sales of short-term investments         3,853,543 320,942  
Loss on disposal of fixed assets         334,297 157,666  
Gain on remeasurement of investment in Geneos         0 (165,215)  
(Gain) loss on equity investment in affiliated entity (156,745)   934,015   (773,384) 1,471,743  
Share of net loss in Geneos 0   0   0 2,165,213  
Net unrealized (gain) loss on available-for-sale equity securities (922,941)   3,967,101   (4,141,156) 8,807,742  
Changes in operating assets and liabilities:              
Accounts receivable, including from affiliated entities         6,621,990 (3,339,490)  
Prepaid expenses and other current assets, including from affiliated entities         41,191,898 (17,590,402)  
Other assets         17,154 655,650  
Accounts payable and accrued expenses, including due to affiliated entities         (43,955,799) 58,090,822  
Accrued clinical trial expenses         (4,421,691) (203,397)  
Deferred revenue, including from affiliated entity         0 8,953,565  
Operating lease right-of-use assets and liabilities, net         (1,406,066) (1,272,391)  
Grant funding liability, including from affiliated entity         1,185,913 (1,730,316)  
Other liabilities         0 (14,826)  
Net cash used in operating activities         (68,979,134) (112,410,075)  
Cash flows from investing activities:              
Purchases of investments         (106,741,680) (139,377,240)  
Proceeds from sale or maturity of investments         173,898,007 153,122,784  
Purchases of capital assets         (320,898) (717,212)  
Proceeds from sale of capital assets         6,071,000 0  
Investment in Geneos         0 (1,999,998)  
Net cash provided by investing activities         72,906,429 11,028,334  
Cash flows from financing activities:              
Proceeds from issuance of common stock, net of issuance costs         2,915,179 72,521,372  
Proceeds from stock option exercises         0 189,522  
Taxes paid related to net share settlement of equity awards         (456,996) (1,349,733)  
Net cash provided by financing activities         2,458,183 71,361,161  
Effect of exchange rate changes on cash and cash equivalents         (2,294) (21,340)  
Increase (Decrease) in cash and cash equivalents         6,383,184 (30,041,920)  
Cash and cash equivalents, beginning of period   $ 46,329,359   $ 71,143,778 46,329,359 71,143,778 $ 71,143,778
Cash and cash equivalents, end of period $ 52,712,543   $ 41,101,858   52,712,543 41,101,858 $ 46,329,359
Supplemental disclosures:              
Amounts accrued for purchases of fixed assets         0 67,645  
Interest paid         533,487 533,487  
Issuance of common stock as part of litigation settlement         $ 14,000,000 $ 0